Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Perivascular inflammation is a prominent pathologic feature in most animal models of
pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling
of the precapillary pulmonary arteries, with excessive proliferation of vascular cells. Although …

Inflammatory processes are prominent in various types of human and experimental
pulmonary hypertension (PH) and are increasingly recognized as major pathogenic …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Rationale: Pulmonary arterial hypertension in association with connective tissue disease
(CTD-PAH) has historically had a poor prognosis, with a 1-year survival rate among patients …

Background REVEAL (the Registry to Evaluate Early and Long-term Pulmonary Arterial
Hypertension Disease Management) is the largest US cohort of patients with pulmonary …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …